```html

Orbitopathy (Thyroid Eye Disease) – A Complete Patient Guide

Overview

Orbitopathy, also known as Thyroid Eye Disease (TED) or Graves’ ophthalmopathy, is an autoimmune inflammatory condition that affects the tissues surrounding the eyes. The disease can cause swelling of the eyelids, protrusion of the eyeballs (proptosis), double vision, and, in severe cases, vision loss.

Who it affects: TED is most commonly associated with autoimmune thyroid disease, particularly Graves’ disease, but it can also occur in patients with Hashimoto’s thyroiditis or in individuals with no thyroid dysfunction at all.

Prevalence: Approximately 25–50 % of patients with Graves’ disease develop some degree of orbitopathy, and about 5 % experience severe, sight‑threatening disease. The overall incidence in the United States is estimated at 16 per 100,000 person‑years, with a higher prevalence in women (≈3:1) and a peak age of onset between 30 and 50 years.<sup>1</sup>

Symptoms

Symptoms can range from mild discomfort to disabling visual impairment. They often appear in the active phase (lasting 6‑24 months) and may improve, stabilize, or progress to a chronic phase.

• Eyelid swelling (periorbital edema): Puffy, tender lids that may feel gritty.
• Eyelid retraction: The upper lid pulls back, exposing more of the white of the eye (often described as a “staring” appearance).
• Proptosis (eye bulging): Forward displacement of the globe, giving a “bulging eyes” look.
• Double vision (diplopia): Occurs when swollen extra‑ocular muscles restrict eye movement.
• Redness and conjunctival injection: The whites of the eyes may appear pink or blood‑shot.
• Dryness, irritation, or grittiness: Due to incomplete eyelid closure (lagophthalmos).
• Pain or pressure sensation: Particularly behind the eye, often worse with movement.
• Difficulty reading or driving: Resulting from diplopia or blurred vision.
• Optic nerve compression: In severe cases this causes vision loss, color desaturation, or a pale optic disc.
• Light sensitivity (photophobia): Common when the cornea is exposed.
• Changes in appearance affecting self‑esteem: Psychological impact is significant and should be acknowledged.

Causes and Risk Factors

Underlying mechanism

TED is an autoimmune process. The body’s immune system mistakenly attacks the fibroblasts and adipocytes (fat cells) behind the eye. This leads to:

1. Inflammation and cytokine release (e.g., TNF‑α, IFN‑γ, IL‑6).
2. Production of excess glycosaminoglycans, causing tissue swelling.
3. Expansion of orbital fat and enlargement of extra‑ocular muscles.

These changes increase orbital pressure, resulting in the characteristic signs of the disease.<sup>2</sup>

Risk factors

• Autoimmune thyroid disease: Up to 90 % of patients have Graves’ disease; ~15 % have Hashimoto’s thyroiditis.
<
• Smoking: Smokers are 3–8 times more likely to develop severe TED; smoking also hinders response to treatment.<sup>3</sup>
• Gender: Women develop TED more often, but men are more likely to have severe disease.
• Age: Peak incidence in the 3rd–5th decade; older age predicts a poorer visual prognosis.
• Radiation exposure to the head/neck: May trigger or worsen disease.
• Genetic predisposition: Certain HLA types (e.g., HLA‑DRB1*03) have been linked to higher risk.
• Rapid changes in thyroid hormone levels: Both overt hyperthyroidism and aggressive antithyroid treatment can precipitate orbitopathy.

Diagnosis

Diagnosis relies on a combination of clinical assessment, laboratory testing, and imaging.

Clinical examination

• Measurement of proptosis with a Hertel exophthalmometer.
• Assessment of extra‑ocular muscle motility to document diplopia.
• Evaluation of lid position, corneal exposure, and signs of optic nerve compromise.

Laboratory tests

• Thyroid function tests: TSH, free T4, free T3 to identify hyper‑ or hypothyroidism.
• Thyroid autoantibodies: Thyroid‑stimulating immunoglobulin (TSI) or TSH‑receptor antibodies (TRAb) are present in >85 % of Graves’ patients with TED.
• Inflammatory markers (ESR, CRP) may be elevated during the active phase.

Imaging

• Orbital MRI: Best for evaluating muscle inflammation and orbital fat expansion.
• CT scan: Helpful for bony anatomy and planning surgeries; can also detect optic nerve compression.

Activity scoring

The Clinical Activity Score (CAS) grades inflammation on a 0–7 scale. A score ≥3 out of 7 usually indicates active disease that may respond to immunosuppressive therapy.<sup>4</sup>

Treatment Options

Treatment is individualized based on disease activity, severity, and the patient’s thyroid status.

1. Manage the underlying thyroid disorder

• Antithyroid drugs (e.g., methimazole, propylthiouracil) to achieve euthyroidism.
• Radioactive iodine (RAI) therapy: May worsen TED, especially in smokers; prophylactic steroids are often given.
• Surgical thyroidectomy: Considered when RAI is contraindicated or in severe disease.

2. Anti‑inflammatory and immunomodulatory therapy

• Systemic glucocorticoids: Prednisone 0.5–1 mg/kg/day for 4–6 weeks, then taper. Effective for active inflammation but long‑term side effects limit use.
• IV methylprednisolone: Preferred for severe active disease; typical regimen is 500 mg weekly for 6 weeks.
• Biologic agents:
  • Teprotumumab: An IGF‑1R antagonist approved by the FDA (2020) that reduces proptosis and diplopia in many patients.<sup>5</sup>
  • Rituximab: Anti‑CD20 monoclonal antibody; evidence mixed, considered in refractory cases.
  • Tocilizumab: IL‑6 receptor blocker; useful when steroids are contraindicated.
• Orbital radiation: Low‑dose external beam radiation (20 Gy in 10 fractions) can shrink inflamed tissue and improve diplopia.

3. Surgical interventions (usually after the disease has stabilized for ≥6 months)

• Eyelid surgery: To correct retraction or excess skin.
• Orbital decompression: Removes bone/fat to relieve pressure on the optic nerve and reduce proptosis.
• Strabismus (muscle) surgery: Aligns the eyes when diplopia persists.
• Lacrimal or ocular surface procedures: Moisture chamber lenses or tarsorrhaphy for severe exposure keratopathy.

4. Lifestyle and supportive measures

• Smoking cessation: The single most effective modifiable factor.
• Artificial tears and lubricating ointments: Prevent corneal drying.
• Head elevation and cool compresses: Reduce overnight eyelid swelling.
• Prism glasses: Help manage mild diplopia.

Living with Orbitopathy (Thyroid Eye Disease)

Daily management tips

1. Protect the ocular surface: Use preservative‑free artificial tears 4–6 times daily; apply ointment at bedtime if eyelids do not close fully.
2. Monitor vision: Keep a simple log of visual changes (blur, color loss, new double vision) and report worsening to your ophthalmologist promptly.
3. Manage dryness and irritation: Wear sunglasses outdoors to shield from wind and UV light.
4. Maintain thyroid balance: Regular blood tests every 3–6 months; never stop medication without consulting your endocrinologist.
5. Stay active, but avoid activities that increase intra‑ocular pressure: Heavy lifting, Valsalva maneuvers, or prolonged prone positioning can exacerbate proptosis.
6. Nutrition and hydration: A balanced diet supports immune regulation; limit excessive iodine intake (e.g., kelp supplements) which can destabilize thyroid function.
7. Emotional health: Join support groups (e.g., Graves’ Ophthalmopathy Support Group) and consider counseling if cosmetic changes affect self‑esteem.

Prevention

Because the disease is autoimmune, true primary prevention is limited, but risk can be markedly reduced:

• Never smoke: If you already smoke, seek cessation programs; nicotine replacement, pharmacotherapy (e.g., varenicline), and counseling are effective.
• Early treatment of thyroid dysfunction: Prompt control of hyperthyroidism reduces the chance of developing orbitopathy.
• Avoid unnecessary radioactive iodine: Discuss alternative therapies with your endocrinologist, especially if you have risk factors for eye disease.
• Regular ophthalmic screening: Patients with Graves’ disease should have baseline eye exams and follow‑up at least annually.

Complications

If left untreated or inadequately managed, TED can lead to serious outcomes:

• Optic neuropathy: Permanent vision loss.
• Corneal ulceration or perforation: Due to chronic exposure.
• Severe diplopia: Interferes with reading, driving, and occupational tasks.
• Cosmetic disfigurement: Persistent proptosis and lid retraction may cause psychosocial distress.
• Secondary infections: Stagnant tears and exposure raise the risk of conjunctivitis or keratitis.
• Systemic side effects from prolonged steroids: Osteoporosis, diabetes, hypertension, and mood changes.

When to Seek Emergency Care

---

Sources:

1. Mayo Clinic. “Graves’ disease.” Mayo Clinic Proceedings, 2022.
2. American Thyroid Association. “Clinical Practice Guidelines for Thyroid Eye Disease.” Thyroid, 2021.
3. Centers for Disease Control and Prevention (CDC). “Smoking & Graves’ disease.” 2023.
4. Van Dijk, J. W. et al. “Clinical Activity Score for Thyroid Eye Disease.” Ophthalmology, 2020.
5. FDA. “Teprotumumab (Tepezza) FDA Approval Letter.” 2020.

```